Brand Name(s):Nivestim, Zarzio, Ratiograstim, Neupogen, Accofil
MHRA Drug Safety Update 2014
Capillary leak syndrome (CLS) has been reported in recipients of filgrastim, including patients undergoing chemotherapy and a healthy donor undergoing peripheral blood progenitor-cell mobilisation; it has also been reported in recipients of pegfilgrastim undergoing chemotherapy. Episodes varied in severity and frequency. CLS is characterised by: hypotension and oedema; hypoalbuminaemia; and haemoconcentration, and may be fatal unless promptly diagnosed and managed.
Prescribers should monitor patients and healthy donors for signs and symptoms of CLS, and should give standard symptomatic treatment immediately if symptoms occur. Advise patients to seek medical attention immediately if they experience symptoms of CLS
Further info at:http://www.mhra.gov.uk/Safetyinformation/DrugSafetyUpdate/CON314895